EN DE

UCrest Berhad, an investment holding company, (0005) Fair Value & Analysis

Healthcare · MY · Market cap 48.3M MYR

UB UCrest Berhad, an investment holding company, 0005 · KLSE
Price0.0600 MYR
Fair Value0.1008 MYR
Upside+68.0%
Quality45/100
Watch UCrest Berhad, an investment holding company, for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Solidly profitable · 15.1% net margin
generates free cash flow
Ranks above peers (8/11)
Narrow moat 36/100
Evidence: High Range 0.0748 MYR – 0.1203 MYR Share as image

Fair value as of: Jul 17, 2026

From 24 valuation models · updated 21 days ago

Share price −7.7% over the past month.

Below-average quality, screening 68% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (0.0748 MYR). The market is more pessimistic than our downside scenario.
  • Solid quality (45/100) at a price below fair value, the discount is the argument here, not the business quality.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

0.5950 MYR 0.0550 MYR Fair Value 0.1008 MYR Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.

How to read this chart

60‑month range 0.0550 MYR – 0.5950 MYR · fair‑value band 0.0748 MYR – 0.1203 MYR · the 0.0600 MYR price screens below the 0.1008 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

UCrest Berhad, an investment holding company, (0005) currently trades at 0.0600 MYR, while our model-based Fair Value estimate is 0.1008 MYR, implying the stock looks roughly 68.0% undervalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, UCrest Berhad, an investment holding company, generated revenue of 14.0M MYR at a net margin of 15.1%. Revenue declined 44.8% year over year. It earns a return on equity of 4.9%. Fundamentals as of Jul 17, 2026

Our scenario range runs from 0.0748 MYR (bear case) to 0.1203 MYR (bull case); at 0.0600 MYR, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 40% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at 68%, 0005 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Growth DCF 0.0400 MYR 0.0600 MYR 0.0900 MYR 72
Growth-Adj P/E 0.1200 MYR 0.1700 MYR 0.2200 MYR 68
Rev-Margin DCF 0.0500 MYR 0.0900 MYR 0.1400 MYR 67
All 24 models by family
DCF Models
FCF DCF 0.0400 MYR 0.0600 MYR 0.1000 MYR 38
Owner Earnings 0.0800 MYR 0.1500 MYR 0.2600 MYR 31
5Y Revenue Exit 0.0500 MYR 0.0900 MYR 0.1500 MYR 39
5Y EBITDA Exit 0.0600 MYR 0.1100 MYR 0.1900 MYR 41
5Y P/E Exit 0.0800 MYR 0.1600 MYR 0.2600 MYR 38
10Y Revenue Exit 0.0500 MYR 0.0800 MYR 0.1200 MYR 36
10Y EBITDA Exit 0.0500 MYR 0.1000 MYR 0.1800 MYR 37
10Y P/E Exit 0.0600 MYR 0.1300 MYR 0.2300 MYR 35
Earnings-Based
Graham-Dodd 0.0400 MYR 0.2900 MYR 0.4100 MYR 54
Lynch FV 0.0900 MYR 0.1200 MYR 0.1600 MYR 50
PEG = 1.0 0.0900 MYR 0.1200 MYR 0.1600 MYR 46
EPV 0.0500 MYR 0.0600 MYR 0.0600 MYR 59
Multiples
P/E Multiple 0.1000 MYR 0.1300 MYR 0.1600 MYR 63
P/S Multiple 0.0500 MYR 0.0600 MYR 0.0800 MYR 58
P/B Multiple 0.0800 MYR 0.1100 MYR 0.1400 MYR 55
EV/EBIT 0.1000 MYR 0.1300 MYR 0.1600 MYR 53
EV/EBITDA 0.0800 MYR 0.1000 MYR 0.1200 MYR 54
EV/Revenue 0.0500 MYR 0.0700 MYR 0.0900 MYR 43
Asset-Based
NCAV (Graham) 0.0300 MYR 0.0400 MYR 0.0600 MYR 50
Growth DCF
Growth DCF 0.0400 MYR 0.0600 MYR 0.0900 MYR 72
Rev-Margin DCF 0.0500 MYR 0.0900 MYR 0.1400 MYR 67
Economic Profit
Residual Income 0.0500 MYR 0.0500 MYR 0.0600 MYR 61
ROIC Compounder 0.0500 MYR 0.0600 MYR 0.0700 MYR 67
Growth Earnings
Growth-Adj P/E 0.1200 MYR 0.1700 MYR 0.2200 MYR 68

Widest divergence: Growth Earnings (0.1700 MYR) versus Asset-Based (0.0400 MYR). Highest evidence: Growth DCF (72).

Key figures & financial health

Revenue (TTM) 14.0M MYR
Revenue growth (YoY) -44.8%
Net margin 15.1%
Return on equity 4.9%
Free cash flow 2.1M MYR FY2024
Operating margin -22.0%
More key figures
EPS growth (YoY) -59.0%

Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 45/100

Of which business quality 56 · Market factors (momentum, volatility) 31

Profitability 47
Margins and returns on capital today
Quality Growth 41
Are margins and returns improving?
Cashflow 51
Earnings quality: real cash, not paper profit
Fin. Strength 92
Balance sheet, leverage, solvency risk
Investment 45
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 29
Price trend over the last 3–12 months (market factor)
52W Momentum 14
Distance to the 52-week high (market factor)
Net Issuance 48
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

UCrest Berhad, an investment holding company, engages in the design, development, and marketing of information technology related products and services in Malaysia and Singapore.

Full company description

UCrest Berhad, an investment holding company, engages in the design, development, and marketing of information technology related products and services in Malaysia and Singapore. The company offers iMedic cloud hospital that is used by doctors and patients for the diagnosis, management, and treatment of chronic diseases, such as cardiovascular diseases (CVD), cancer, diabetes, hypertension, sleep apnea, stroke rehabilitation, and other diseases in the United States, China, Singapore, Malaysia, Taiwan, Indonesia, Vietnam, and the Middle East. It also provides mobile healthcare services. The company was formerly known as Palette Multimedia Berhad and changed its name to UCrest Berhad in November 2017. UCrest Berhad was incorporated in 1997 and is based in Petaling Jaya, Malaysia.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2020 – FY2024 · reported fiscal years

UCrest Berhad, an investment holding company, reported revenue of 18.1M MYR in FY2024 versus 25.5M MYR in FY2020, a compound −8.2%/yr. Reported net income was 4.7M MYR in FY2024, compounding −20.0%/yr from FY2020.

Growth Quality 64/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2024)
18.1M MYR
Latest YoY
+13.7%
Avg. growth/yr (3Y)
+13.6%
Avg. growth/yr (5Y)
+8.1%
Avg. growth/yr (9Y)
+19.6%
Revenue −8.2%/yr
FY20 25.5M MYR
FY21 12.3M MYR
FY22 13.6M MYR
FY23 15.9M MYR
FY24 18.1M MYR
Net income −20.0%/yr
FY20 11.6M MYR
FY21 −35.1M MYR
FY22 101K MYR
FY23 4.2M MYR
FY24 4.7M MYR

Watch 0005: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "UCrest Berhad, an investment holding company, Fair Value". https://www.fairvalue-calculator.com/stock/0005

Peer Group

Health Information Services · 127 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 45 · Below median
Fair Value upside +67% · Top 25%
Return on equity (TTM) 5% · Above median
Return on assets 1% · Above median
Net margin (TTM) 15% · Top 25%
Operating margin (TTM) -22% · Bottom 25%
Revenue growth -45% · Bottom 25%

Valuation Multiples vs Health Information Services median · lower = cheaper

P/B 0.27× · Cheaper than 75% of peers
P/S (TTM) 0.84× · Cheaper than 75% of peers
P/FCF 5.7× · Cheaper than median
EV/EBITDA 2.6× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 0
FUTURE 0 · sector 29
PAST 20 · sector 7
HEALTH 0 · sector 98
DIVIDEND 0 · sector 35

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $190.12 $95.12 -50%
Pro Medicus Limited PME A$194.84 A$23.74 -88%
BrightSpring Health Services, Inc BTSG $68.16 $21.31 -69%
HealthEquity, Inc HQY $97.67 $56.63 -42%
Hinge Health, Inc HNGE $88.80 $24.03 -73%
10x Genomics, Inc TXG $45.75 $17.18 -62%
Waystar Holding WAY $22.69 $12.86 -43%
Doximity, Inc DOCS $22.21 $17.18 -23%
Privia Health Group PRVA $28.10 $5.30 -81%
Inventurus Knowledge Solutions Limited IKS ₹1,846 ₹860.28 -53%

Compare UCrest Berhad, an investment holding company, with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is UCrest Berhad, an investment holding company, (0005) overvalued or undervalued?
As of Jul 17, 2026, our model estimates a fair value of 0.1008 MYR versus a price of 0.0600 MYR, about +68% (undervalued).
What is the fair value of 0005?
Our model-based fair value for UCrest Berhad, an investment holding company, is 0.1008 MYR (as of Jul 17, 2026), built from audited fundamentals. The current price is 0.0600 MYR.
What is the quality score of 0005?
UCrest Berhad, an investment holding company, has a Quality Score of 45/100. It combines two groups: business quality (profitability, growth, cash flow, balance-sheet strength) and market factors (price momentum, distance to the 52-week high, volatility). Both subtotals are shown separately in the detail view.
What is the revenue of UCrest Berhad, an investment holding company, (0005)?
UCrest Berhad, an investment holding company, reported trailing-twelve-month revenue of about 14.0M MYR (latest available figure, as of Jul 17, 2026).
What is the net profit margin of 0005?
The net profit margin of UCrest Berhad, an investment holding company, is about 15.1%, meaning it keeps roughly 15.1% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track UCrest Berhad, an investment holding company, and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.